智通财经APP获悉，堃博医疗-B(02216)早盘再涨超12%，月内累计涨幅接近2倍。截至发稿，涨10.2%，报2.7港元，成交额1278.02万港元。
消息面上，堃博医疗此前发布公告，公司核心产品，自主研发的全球首款经自然腔道射频消融肺癌治疗器械——BroncAblate®智衡®一次性使用肺部射频消融导管正式获得中国国家药品监督管理局(NMPA)批准在中国上市，该产品为全球首款通过大规模临床循证医学证据验证的经自然腔道肺癌射频消融器械，引领肺癌治疗进入超微创介入治疗时代。
值得注意的是，近日，央视网、人民网等以《经支气管射频消融治疗肺部肿瘤技术的主要应用》为题，深度报道了我国在肺部肿瘤微创治疗领域的重要突破—经支气管射频消融技术的临床应用成果。该技术依托堃博医疗自主研发的BroncAblate智衡肺部射频消融系统，创新性融合LungPro增强现实光学全肺诊疗导航系统，通过人体自然腔道支气管路径构建精准诊疗通道，将消融电极精准送达病灶中心区域。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.